Low Back Pain – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Low Back Pain – Pipeline Review, H2 2016’, provides an overview of the Low Back Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Low Back Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Low Back Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Low Back Pain

The report reviews pipeline therapeutics for Low Back Pain by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Low Back Pain therapeutics and enlists all their major and minor projects

The report assesses Low Back Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Low Back Pain

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Low Back Pain

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Low Back Pain pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adynxx, Inc.

Aestus Therapeutics, Inc.

Array BioPharma Inc.

Axsome Therapeutics Inc

Boehringer Ingelheim GmbH

Egalet Corporation

Frontier Biotechnologies Co., Ltd

Gador S.A.

Grunenthal GmbH

Hisamitsu Pharmaceutical Co., Inc.

Immune Pharmaceuticals Inc.

KPI Therapeutics, Inc.

MD Biosciences GmbH

Mesoblast Limited

Nektar Therapeutics

Orion Oyj

Pacira Pharmaceuticals, Inc.

Pfizer Inc.

Stayble Therapeutics AB

Sun Pharma Advanced Research Company Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Low Back Pain Overview 8

Therapeutics Development 9

Pipeline Products for Low Back Pain - Overview 9

Low Back Pain - Therapeutics under Development by Companies 10

Low Back Pain - Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Low Back Pain - Products under Development by Companies 15

Low Back Pain - Companies Involved in Therapeutics Development 16

Adynxx, Inc. 16

Aestus Therapeutics, Inc. 17

Array BioPharma Inc. 18

Axsome Therapeutics Inc 19

Boehringer Ingelheim GmbH 20

Egalet Corporation 21

Frontier Biotechnologies Co., Ltd 22

Gador S.A. 23

Grunenthal GmbH 24

Hisamitsu Pharmaceutical Co., Inc. 25

Immune Pharmaceuticals Inc. 26

KPI Therapeutics, Inc. 27

MD Biosciences GmbH 28

Mesoblast Limited 29

Nektar Therapeutics 30

Orion Oyj 31

Pacira Pharmaceuticals, Inc. 32

Pfizer Inc. 33

Stayble Therapeutics AB 34

Sun Pharma Advanced Research Company Ltd. 35

Low Back Pain - Therapeutics Assessment 36

Assessment by Monotherapy Products 36

Assessment by Combination Products 37

Assessment by Target 38

Assessment by Mechanism of Action 40

Assessment by Route of Administration 42

Assessment by Molecule Type 44

Drug Profiles 46

(loxoprofen + methocarbamol) - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

AB-001 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

ARRY-954 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

ATX-09002 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

AYX-2 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

bupivacaine - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

cebranopadol - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

dexmedetomidine hydrochloride - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Drug for Chronic Low Back Pain - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

HP-3150 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

IG-8801 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

lidocaine hydrochloride - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

MD-22 - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

MPC-06ID - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

NKTR-181 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

oxycodone hydrochloride ER - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

SPARC-1401 - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

tanezumab - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

U-2902 - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

zoledronic acid - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

Low Back Pain - Dormant Projects 80

Low Back Pain - Discontinued Products 82

Low Back Pain - Product Development Milestones 83

Featured News & Press Releases 83

Aug 01, 2016: MesoblastS Full 24-Month Trial Results for Chronic Low Back Pain Presented at Spine Intervention Society Annual Meeting, Receive Award for Best Basic Science 83

Jun 22, 2016: Frontier Biotech Reports Primary Endpoint Met in Phase 2 Trial of AB001 In Chronic Low Back Pain 84

Feb 29, 2016: Cebranopadol Top-Line Data From Phase IIb Trial in Chronic Lower Back Pain Demonstrate Clinically and Statistically Significant Improvements in Pain Across All Arms 84

Feb 25, 2015: Nektar Announces Start of Phase 3 SUMMIT-07 Study of NKTR-181 in Patients with Chronic Low Back Pain 85

Appendix 87

Methodology 87

Coverage 87

Secondary Research 87

Primary Research 87

Expert Panel Validation 87

Contact Us 87

Disclaimer 88

List of Tables

List of Tables

Number of Products under Development for Low Back Pain, H2 2016 9

Number of Products under Development by Companies, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Development, H2 2016 14

Products under Development by Companies, H2 2016 15

Low Back Pain – Pipeline by Adynxx, Inc., H2 2016 16

Low Back Pain – Pipeline by Aestus Therapeutics, Inc., H2 2016 17

Low Back Pain – Pipeline by Array BioPharma Inc., H2 2016 18

Low Back Pain – Pipeline by Axsome Therapeutics Inc, H2 2016 19

Low Back Pain – Pipeline by Boehringer Ingelheim GmbH, H2 2016 20

Low Back Pain – Pipeline by Egalet Corporation, H2 2016 21

Low Back Pain – Pipeline by Frontier Biotechnologies Co., Ltd, H2 2016 22

Low Back Pain – Pipeline by Gador S.A., H2 2016 23

Low Back Pain – Pipeline by Grunenthal GmbH, H2 2016 24

Low Back Pain – Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2016 25

Low Back Pain – Pipeline by Immune Pharmaceuticals Inc., H2 2016 26

Low Back Pain – Pipeline by KPI Therapeutics, Inc., H2 2016 27

Low Back Pain – Pipeline by MD Biosciences GmbH, H2 2016 28

Low Back Pain – Pipeline by Mesoblast Limited, H2 2016 29

Low Back Pain – Pipeline by Nektar Therapeutics, H2 2016 30

Low Back Pain – Pipeline by Orion Oyj, H2 2016 31

Low Back Pain – Pipeline by Pacira Pharmaceuticals, Inc., H2 2016 32

Low Back Pain – Pipeline by Pfizer Inc., H2 2016 33

Low Back Pain – Pipeline by Stayble Therapeutics AB, H2 2016 34

Low Back Pain – Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016 35

Assessment by Monotherapy Products, H2 2016 36

Assessment by Combination Products, H2 2016 37

Number of Products by Stage and Target, H2 2016 39

Number of Products by Stage and Mechanism of Action, H2 2016 41

Number of Products by Stage and Route of Administration, H2 2016 43

Number of Products by Stage and Molecule Type, H2 2016 45

Low Back Pain – Dormant Projects, H2 2016 80

Low Back Pain – Dormant Projects (Contd..1), H2 2016 81

Low Back Pain – Discontinued Products, H2 2016 82

List of Figures

List of Figures

Number of Products under Development for Low Back Pain, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy Products, H2 2016 36

Number of Products by Targets, H2 2016 38

Number of Products by Stage and Targets, H2 2016 38

Number of Products by Top 10 Mechanism of Actions, H2 2016 40

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 40

Number of Products by Top 10 Routes of Administration, H2 2016 42

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 42

Number of Products by Molecule Types, H2 2016 44

Number of Products by Stage and Molecule Types, H2 2016 44

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports